Xarelto（拜瑞妥）上市了吗？

Rivaroxaban (Xarelto) is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson. On September 15 and October 1, 2008, rivaroxaban (Xarelto) received marketing approval in Canada and the European Union respectively. In China, rivaroxaban (Xarelto) was approved for marketing by the State Food and Drug Administration in March 2009, and was successfully included in the 2009 National Medical Insurance List in the same year. On July 1, 2011, the FDA approved rivaroxaban (Xarelto) for the prevention of deep vein thrombosis in patients undergoing knee or hip replacement surgery.

At present, the incidence of thrombotic diseases is extremely high, and it has a high disability and mortality rate. Its occurrence and development are mainly caused by vascular endothelial damage, increased blood coagulability, increased platelet number and activity, and reduced anticoagulant activity. In recent years, new anticoagulant drugs Factor Xa (FXa) inhibitors have received more and more attention among anticoagulant drugs, among which rivaroxaban (Xarelto) is a representative drug of FXa inhibitors. Rivaroxaban (Xarelto) is the world's first oral direct factor Xa inhibitor that can highly selectively and competitively inhibit free and bound factor It has the characteristics of high bioavailability, wide spectrum of disease treatment, stable dose-effect relationship, convenient oral administration and low risk of bleeding. Rivaroxaban (Xarelto) is also a drug used to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.